COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Ferreira, P. [1 ]
Senna, T. [1 ]
Sebastiao, M. [1 ]
Alexandre, R. F. [1 ]
Almeida, P. [1 ]
机构：
[1] Pfizer, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE52
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [32] BRIGATINIB COMPARED WITH CRIZOTINIB AND ALECTINIB IN PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASES AT DIAGNOSIS: A COST-EFFECTIVENESS ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Genov, I
    Mendes da Silva, B.
    Lanchoti Fiori, G. M.
    Villas Boas, B.
    Teixeira Chadid, T.
    Regis, C.
    VALUE IN HEALTH, 2021, 24 : S31 - S32
  • [33] Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system
    Cazarim, Maurilio de Souza
    Vilela Rodrigues, Joao Paulo
    Coelho da Cruz-Cazarim, Estael Luzia
    Ayres, Lorena Rocha
    Leira Pereira, Leonardo Regis
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 53 (03)
  • [34] Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Shang, Yuqi
    Guo, Hao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (03) : 367 - 372
  • [35] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [36] Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [37] First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    BMJ OPEN, 2023, 13 (12):
  • [38] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [39] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Graham, Donna M.
    Djalalov, Sandjar
    Beca, Jaclyn
    Hoch, Jeffrey
    Tsao, Ming S.
    Cutz, Jc
    Leighl, Natasha
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1317 - S1318
  • [40] PANITUMUMAB+MFOLFOX6 VERSUS BEVACIZUMAB+MFOLFOX6 AS FIRST LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    dos Santos, R. F.
    Coutinho, M. B.
    Haas, L.
    VALUE IN HEALTH, 2015, 18 (07) : A821 - A821
12345